

CMB OPEN COMPETITION INTRODUCTION

美国中华医学基金会公开竞标项目介绍

By Linda Zhou, MA, the China Medical Board
周娜，硕士，美国中华医学基金会

Over the course of the 20th century, health in China has advanced significantly. Nevertheless, China still faces many challenges in providing universal, high quality, affordable healthcare to its people. The China Medical Board (美国中华医学基金会, CMB) is dedicated to supporting solutions to these challenges as part of its broader mission of promoting health in China and other Asian countries. In strengthening Chinese capacities in **health policy and systems sciences (HPS)** research and **health professional education (HPE)**, the CMB supports China's ongoing health reforms by encouraging the expansion of China's evidence-base for health policymaking.

Under the HPS umbrella strategy, **CMB Open Competition (CMB-OC)** research is designed to nurture individual capacity especially for **junior researchers** from eligible institutions and encourages **multidisciplinary** approaches. The program's strenuous merit-based peer review process seeks to identify excellent researchers or researchers with high potential, regardless of seniority. CMB-OC awards research funding of **25,000 USD - 150,000 USD per project for 2-5 years** and, and entitles awardees **opportunities for future collaborative learning, training, and mentorship**. The CMB-OC program has run for three consecutive years since 2011 and has awarded 20 grants with funding ranging from 57,000 USD to 150,000 USD. The program is highly competitive. For instance, in the 2012 cycle, CMB received 123 project applications, of which 29 abstracts were invited for full proposal development. Ultimately, 8 projects were approved for funding.

The CMB-OC supports projects in the following broad areas of HPS. As a central theme, in 2013 CMB-OC will prioritize equity in health and give special attention to the research that illuminates the measurement, causes, conditions, strategies and interventions to inequity in health.

- *Emerging health challenges in China*, especially research involving diseases with a high burden of disease in China (but excluding wet-lab based research); and
- *Health policies and health systems responses to address emerging health challenges*, such as those related to health governance, ethics, financing, human resources, care delivery systems, health technology assessment, pharmaceutical policies, and health informatics.